Clinical targeting of the TNF and TNFR superfamilies

被引：368

作者：

Croft, Michael ^{[1
]}

Benedict, Chris A. ^{[1
]}

Ware, Carl E. ^{[2
]}

机构：

[1] La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA 92037 USA

[2] Sanford Burnham Med Res Inst, Infect & Inflammatory Dis Ctr, Lab Mol Immunol, La Jolla, CA 92037 USA

来源：

NATURE REVIEWS DRUG DISCOVERY | 2013年 / 12卷 / 02期

基金：

美国国家卫生研究院;

关键词：

ANTI-CD40; MONOCLONAL-ANTIBODY; RELAPSED/REFRACTORY MULTIPLE-MYELOMA; SYSTEMIC-LUPUS-ERYTHEMATOSUS; COLLAGEN-INDUCED ARTHRITIS; CELL MATURATION ANTIGEN; B-LYMPHOCYTE STIMULATOR; VERSUS-HOST-DISEASE; CYTOKINE 1A TL1A; DEATH RECEPTOR 5; T-CELL;

D O I：

10.1038/nrd3930

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Inhibitors of tumour necrosis factor (TNF) are among the most successful protein-based drugs (biologics) and have proven to be clinically efficacious at reducing inflammation associated with several autoimmune diseases. As a result, attention is focusing on the therapeutic potential of additional members of the TNF superfamily of structurally related cytokines. Many of these TNF-related cytokines or their cognate receptors are now in preclinical or clinical development as possible targets for modulating inflammatory diseases and cancer as well as other indications. This Review focuses on the biologics that are currently in clinical trials for immune-related diseases and other syndromes, discusses the successes and failures to date as well as the expanding therapeutic potential of modulating the activity of this superfamily of molecules.

引用

页码：147 / 168

页数：22

共 220 条

[21] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[22] CD95, BIM and T cell homeostasis [J].

Bouillet, Philippe ;

O'Reilly, Lorraine A. .

NATURE REVIEWS IMMUNOLOGY, 2009, 9 (07) :514-519

[23] A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J].

Boumpas, DT ;

Furie, R ;

Manzi, S ;

Illei, GG ;

Wallace, DJ ;

Balow, JE ;

Vaishnaw, A .

ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :719-727

[24] Tanezumab Reduces Osteoarthritic Knee Pain: Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial [J].

Brown, Mark T. ;

Murphy, Frederick T. ;

Radin, David M. ;

Davignon, Isabelle ;

Smith, Michael D. ;

West, Christine R. .

JOURNAL OF PAIN, 2012, 13 (08) :790-798

[25] Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease [J].

Browning, Jeffrey L. .

IMMUNOLOGICAL REVIEWS, 2008, 223 :202-220

[26]

Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731

[27] TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses [J].

Burkly, Linda C. ;

Michaelson, Jennifer S. ;

Zheng, Timothy S. .

IMMUNOLOGICAL REVIEWS, 2011, 244 :99-114

[28] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia [J].

Byrd, John C. ;

Kipps, Thomas J. ;

Flinn, Ian W. ;

Cooper, Maureen ;

Odenike, Olatoyosi ;

Bendiske, Jennifer ;

Rediske, John ;

Bilic, Sanela ;

Dey, Jyotirmoy ;

Baeck, Johan ;

O'Brien, Susan .

LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2136-2142

[29] A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies [J].

Camidge, D. Ross ;

Herbst, Roy S. ;

Gordon, Michael S. ;

Eckhardt, S. Gail ;

Kurzrock, Razelle ;

Durbin, Blythe ;

Ing, Josephine ;

Tohnya, Tanyifor M. ;

Sager, Jason ;

Ashkenazi, Avi ;

Bray, Gordon ;

Mendelson, David .

CLINICAL CANCER RESEARCH, 2010, 16 (04) :1256-1263

[30] TACI is mutant in common variable immunodeficiency and IgA deficiency [J].

Castigli, E ;

Wilson, SA ;

Garibyan, L ;

Rachid, R ;

Bonilla, F ;

Schneider, L ;

Geha, RS .

NATURE GENETICS, 2005, 37 (08) :829-834

← 1 2 3 4 5 6 7 8 9 10 →